Cannabis Breakthrough: VER-01 Shines in Pain Management Trials
VER-01, a cannabis-derived medication developed by Vertanical, demonstrated superior effectiveness and safety compared to placebo and opioids in late-stage trials for chronic lower back pain. It also improved sleep and quality of life. A cysteine-rich diet may aid intestinal recovery from chemotherapy, showcasing promising natural intervention possibilities.
An experimental cannabis-derived medication, VER-01, has shown promising results in treating chronic lower back pain, outperforming opioids and placebo in two late-stage trials. Developed by Munich-based Vertanical, the drug not only alleviates pain but also enhances sleep quality and physical function, according to trial reports.
Dr. Charles Argoff of Albany Medical College highlighted the potential impact of VER-01, stating that the Phase 3 studies could offer new hope to millions enduring chronic pain. The studies suggest that VER-01 could provide effective relief while addressing safety concerns associated with current therapies.
In a trial involving 820 patients, VER-01 resulted in a nearly 3-point decrease in pain on a 10-point scale over 12 months. A second trial revealed superior pain control compared to opioids. Meanwhile, research on cysteine-rich diets indicates potential intestinal healing benefits post-chemotherapy.
(With inputs from agencies.)
Google News